 Home > Active Ingredient News > Antitumor Therapy > JCO: Venetog combined with FLAG-IDA can improve the deep remission rate and transplant success rate of newly diagnosed and relapsed/refractory AML

JCO: Venetog combined with FLAG-IDA can improve the deep remission rate and transplant success rate of newly diagnosed and relapsed/refractory AML

 Last Update: 2021-06-04
 Source: Internet
 Author: User

Tags

hct116 cell line

solve 2 3

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

About 60% of newly diagnosed acute myeloid leukemia (ND-AML) patients who have received front-line treatment have achieved complete remission (CR), but about 30%-40% of patients will relapse .

About 60% of newly diagnosed acute myeloid leukemia (ND-AML) patients who have received front-line treatment have achieved complete remission (CR), but about 30%-40% of patients will relapse

This is a phase IB/II clinical trial that evaluated fludarabine, cytarabine, granulocyte colony stimulating factor and idarubicin in combination with the B-cell lymphoma -2 inhibitor Venetog for ND -Safety and effectiveness in patients with AML and R/R-AML.

Lymphoma

The Phase IB part (PIB) of the study recruited R/R-AML patients, using a 3+3 dose escalation and decay algorithm to identify the maximum tolerated dose and dose limiting toxicity.

PFS(A) and OS(B) in different queues

As of the analysis date, a total of 68 patients were enrolled (PIB: 16 cases; PIIA: 29 cases; PIIB: 23 cases).

Grade 3-4 adverse events that occurred in more than 10% of patients included febrile neutropenia (50%), bacteremia (35%), pneumonia (28%), and sepsis (12%) PIB The total remission rates of the PIIA, PIIA, and PIIB cohorts were 75%, 97%, and 70%, respectively, and the complete remission rates were 75%, 90%, and 61%, respectively.

Prognosis of patients with or without HSCT

With a median follow-up of 12 months, the median overall survival (OS) of the two PII cohorts did not reach .

With a median follow-up of 12 months, the median overall survival (OS) of the two PII cohorts did not reach the median follow-up of 12 months, and the median overall survival (OS) of the two PII cohorts did not reach the stem cells

In summary, fludarabine, cytarabine, granulocyte colony stimulating factor, and idarubicin + venetoke are effective intensive treatment options for patients with ND-AML and R/R-AML, which can help Improve the deep remission rate and transplant success rate .

Fludarabine, cytarabine, granulocyte colony stimulating factor, and idarubicin + venetork are effective intensive treatment options for patients with ND-AML and R/R-AML, helping to improve the deep remission rate and Transplant success rate Fludarabine, cytarabine, granulocyte colony stimulating factor, and idarubicin + venetork are effective intensive treatment options for patients with ND-AML and R/R-AML, helping to improve the depth Remission rate and transplant success rate

Original source:

DiNardo Courtney D,Lachowiez Curtis A,Takahashi Koichi et al.

Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia

in this message

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.